FOXM1 and prostate carcinoma: One of the bioinformatics investigations nominated GFAP as a potential regulator of immune phenotypes in prostate cancer (72), yet its role in prostate cancer progression provides a new exciting avenue for further investigation, especially in combination with GADD45B, STAT3, and GFAP (and, potentially, FOXM1).